Table 2.
Logistic analysis of factors that affect clinical benefit.
| Characteristic | Clinical benefit (n, %) | p value (Fisher exact test) | Odds ratio (95% CI) | |
|---|---|---|---|---|
| CB | NCB | |||
| CPS | ||||
| ≥1 | 46 (64.8) | 25 (35.2) | <0.001 | 10.43 (2.78, 39.05) |
| <1 | 3 (15.0) | 17 (85.0) | ||
| 11q13 amplification | ||||
| No | 51 (56.7) | 39 (43.3) | 0.024 | 9.15 (1.08, 77.52) |
| Yes | 1 (12.5) | 7 (87.5) | ||
| EGFR amplification | ||||
| No | 48 (52.7) | 43 (47.3) | 1 | 0.84 (0.18, 3.95) |
| Yes | 4 (57.1) | 3 (42.9) | ||
| EGFR mutation | ||||
| No | 52 (55.9) | 41 (44.1) | 0.020 | 13.92 (0.75, 258.94) |
| Yes | 0 (0) | 5 (100) | ||
CB, clinical benefit; NCB, non-clinical benefit; CPS, combined positive score; 11q13: CCND1_FGF3_FGF4_FGF19 or any one of them.